Beactica Therapeutics initiates IND-enabling studies for BEA‑17, a first-in-class LSD1–CoREST degrader for glioblastoma
Beactica Therapeutics AB, a Swedish precision medicine company, today announced the initiation of IND-enabling studies for BEA-17, the Company’s wholly owned, first-in-class oral degrader of the epigenetic regulators LSD1 and CoREST, being developed as a precision immunotherapy for glioblastoma (GBM). The studies advan…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Günther Lackner appointed EVP and Head of Business Area Connect
- Scandi Standard receives competition clearance for the acquisition of Glenhaven Foods
- Sweden’s leading business school chooses Swedish IT infrastructure from Nordlo
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →